What is Cybin?
Headquartered in Canada and established in 2019, Cybin operates as a specialized biotechnology entity dedicated to the development of psychedelic-based therapeutics. By integrating advanced drug delivery systems with novel formulation approaches, the company addresses significant gaps in the current mental health landscape. Cybin distinguishes itself through a collaborative model, engaging with internationally recognized scientists and a global network of partners to transition experimental compounds into standardized, safe, and effective clinical treatments. Its operational presence in the United States, the United Kingdom, the Netherlands, and Ireland positions the firm as a key player in the global push for innovative psychiatric care.
How much funding has Cybin raised?
Cybin has raised a total of $80M across 2 funding rounds:
Share Placement
$30M
Debt
$50M
Share Placement (2023): $30M, investors not publicly disclosed
Debt (2025): $50M, investors not publicly disclosed
Key Investors in Cybin
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Cybin?
With the recent capital injection, Cybin is well-positioned to advance its core therapeutic candidates through critical clinical trial phases. The strategic focus will likely center on optimizing its proprietary drug discovery platforms and refining treatment regimens to meet stringent regulatory standards. As the company moves deeper into its enterprise-level lifecycle, the emphasis will shift toward commercialization readiness and the expansion of its intellectual property portfolio. Investors will be monitoring the firm's ability to translate its research-heavy foundation into scalable, market-ready solutions that address the growing global demand for effective mental health interventions.
See full Cybin company page
